Assessing the impact of Erdafitinib, a FGFR inhibitor, on metastatic urothelial cancer
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 17th, 2024
|
Patients diagnosed with metastatic urothelial cancer are presently undergoing treatment involving cisplatin-based chemotherapy. However, the eligibility criteria for this therapy are quite stringent, and its efficacy in managing the disease is limited. Additionally, second-line treatments utilizing PD-1 and PD-L1 inhibitors have proven ineffective. Hence, there's a pressing need for new interventions. Given that approximately one-fifth of these patients possess a mutation in the fibroblast growth factor receptor (FGFR), a study was conducted to evaluate the effectiveness of an FGFR inhibitor called Erdafitinib in addressing metastatic urothelial cancer.
The phase 3 clinical trial enrolled 266 patients who were diagnosed with metastatic and unresectable urothelial carcinoma with mutations in the fibroblast growth factor receptor. The average age of the cohort was approximately 66 years old, with over two-thirds having undergone at least two other systemic therapy types previously. Half of the participants received oral Erdafitinib at a dosage of 8 mg, while the remaining half underwent standard chemotherapy using docetaxel or vinflunine. Over a median follow-up duration of 16 months, those treated with Erdafitinib displayed a median survival period of 12.1 months, notably longer than the 7.8 months observed in the control chemotherapy group. This resulted in a 36% reduction in the risk of death attributed to Erdafitinib usage. In terms of disease progression, Erdafitinib exhibited superiority over standard chemotherapy, demonstrating a delay in tumor growth for 5.6 months, representing a 42% lower risk compared to the control group. Notably, there were no significant differences in adverse effects between the two groups, with fatal adverse events being less common among those treated with Erdafitinib.
The phase 3 clinical trial enrolled 266 patients who were diagnosed with metastatic and unresectable urothelial carcinoma with mutations in the fibroblast growth factor receptor. The average age of the cohort was approximately 66 years old, with over two-thirds having undergone at least two other systemic therapy types previously. Half of the participants received oral Erdafitinib at a dosage of 8 mg, while the remaining half underwent standard chemotherapy using docetaxel or vinflunine. Over a median follow-up duration of 16 months, those treated with Erdafitinib displayed a median survival period of 12.1 months, notably longer than the 7.8 months observed in the control chemotherapy group. This resulted in a 36% reduction in the risk of death attributed to Erdafitinib usage. In terms of disease progression, Erdafitinib exhibited superiority over standard chemotherapy, demonstrating a delay in tumor growth for 5.6 months, representing a 42% lower risk compared to the control group. Notably, there were no significant differences in adverse effects between the two groups, with fatal adverse events being less common among those treated with Erdafitinib.